HealthDay News Cannabis use disorder (CUD) is associated with an increased risk for oral cancer, according to a study published in the September issue of Preventive Medicine Reports.

The FDA is expected to decide on treatments for acromegaly, edema, HSCT-associated thrombotic microangiopathy, multiple sclerosis, and spinal muscular atrophy.

CMTX-101 is an investigational immune-enabling antibody designed to target and destroy the pro-inflammatory structure of bacteria biofilms.

The randomized, double-blind, placebo-controlled MODEL trial (ClinicalTrials.gov Identifier: NCT05516992) evaluated the safety and efficacy of SB-01 in 417 adults with CLBP and related disability due ...

The Food and Drug Administration (FDA) has issued another Complete Response Letter (CRL) to Regeneron (CRL) for the Biologics License Application (BLA) for odronextamab in relapsed/refractory ...

Proportion of treated women began to decline 18 months before childbirth, reaching 27.9% at the estimated time of conception.

HealthDay News — People with eating disorders report success with self-medicating with nonprescribed drugs instead of prescription antidepressants, according to a study published online July 22 in ...

David Holtzman, a retired privacy expert, said much of the technology already exists and that past federal efforts to set up similar systems “have proven to be ineffective." ...

Participants did not have islet autoantibodies and had significantly lower median type 1 diabetes genetic risk score.

Rituximab no better than glucocorticoids alone for inducing remission in patients with eosinophilic granulomatosis with polyangiitis.

The Food and Drug Administration (FDA) is requiring class-wide label changes for opioid medications to provide additional information on the risks associated with long-term use.

Pegcetacoplan inhibits C3 activation by binding to C3 and its activation fragment C3b, thereby reducing C3 glomerular fragment deposition in patients with C3G and primary IC-MPGN.